The study was conducted by John M. Inadomi, MD, of the University of Washington School of Medicine, Seattle, and colleagues. They enrolled 997 participants in a randomized clinical trial conducted in the San Francisco Community Health Network, the public healthcare system of San Francisco.
Within 12 months of enrollment, 58 percent completed the colorectal cancer screening strategy they were assigned or chose. However, a significantly lower percentage of participants (38 percent) in the colonoscopy group completed that procedure compared with participants in the fecal occult blood testing group completing that screening (67 percent) or those participants who were allowed to choose their screening (69 percent).
“This study found that limiting the recommendation for colorectal cancer screening to colonoscopy can result in a lower completion rate for colorectal cancer screening compared with providing a choice between FOBT or colonoscopy, especially among ethnic/racial minorities,” the authors commented, according to the release.
The authors also observed significant racial/ethnic differences in screening completion, with whites more often completing colonoscopy and nonwhites more often completing FOBT.
Related Articles on Colorectal Cancer Screening:
Which Procedures Do Surgery Centers Perform Most? 40 Statistics on 4 Common Specialties
Gastroenterologist Dr. Kenneth Shieh Discusses Colorectal Cancer in Local Publication
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
